BLIP directs up to 174 microAmps of 66-202 protons onto targets for isotope production, including Ac225. Similarly, LANL’s Isotope Production Linac (IPL) receives 100 Mev protons from the LANSCE accelerator. IPL can generate up 5-7 kW of beam power on each target for isotope production. Oak Ridge is a reactor laboratory with over 20 years experience in separating Ac225 from fissile U223 via Th209.
One of the challenges for accelerator-produced Ac225 is separation of co-produced Ac227 although biodistribution and toxicity data with 0.3% Ac227 contamination show negligible impact.
The over-arching DOE goal is to produce sufficient material to support clinical trials in 1-2 years and an established drug in about 5 years
Presented By: Kevin John from Los Alamos National Laboratory, Los Alamos, NM
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.